Ratg denied as non-formulary by Humana?

Humana Medicare Advantage plans must follow CMS coverage guidelines, and services must be provided according to Medicare coverage guidelines established by the Centers for Medicare & Medicaid Services (CMS), under which all medical care, services, supplies and equipment must be medically necessary . Under CMS NCD 260.7, the FDA has approved lymphocyte immune globulin, anti-thymocyte globulin (equine) for the management of allograft rejection episodes in renal transplantation, it is covered under Medicare when used for this purpose, and other forms of lymphocyte globulin preparation that the FDA approves for this indication may be covered . The FDA-labeled indication for rabbit ATG is that Thymoglobulin (anti-thymocyte globulin, rabbit) is indicated for the prophylaxis and treatment of acute rejection in adult and pediatric patients receiving a kidney transplant in conjunction with concomitant immunosuppression , with the approved regimen being 1.5 mg/kg of body weight administered daily for 4 to 7 days . Per FDA labeling, Thymoglobulin is contraindicated in patients with a history of allergy or anaphylaxis to rabbit proteins or to any product excipients, or who have active acute or chronic infections that contraindicate any additional immunosuppression , and dose reductions are required when the WBC count is between 2,000 and 3,000 cells/mm3 or if the platelet count is between 50,000 and 75,000 cells/mm3 . Humana requires prior authorization through its transplant network: preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300 or by phone at 866-421-5663 , and Humana MA may apply step therapy requirements for some drugs under its Part B Step Therapy Preferred Drug List. To prevent disruption of care, Humana does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to enrollment, though Humana may review services furnished during an active course of treatment against permissible coverage criteria when determining payment .

- For kidney transplant rejection prophylaxis or treatment, the request aligns squarely with the FDA label: Thymoglobulin is indicated for the prophylaxis and treatment of acute rejection in adult and pediatric patients receiving a kidney transplant in conjunction with concomitant immunosuppression , and the drug is indicated for management of allograft rejection episodes in renal transplantation and is covered under Medicare when used for this purpose per CMS NCD 260.7 - KDIGO clinical practice guidelines support ATG-based induction in kidney transplant recipients, particularly those at high immunologic risk; anti-thymocyte globulin is a highly efficient induction agent that can prevent acute rejection and delayed graft function and is widely used for biopsy-confirmed acute rejection reversal and steroid-resistant rejection - For steroid-resistant or vascular rejection, ATG is the guideline-endorsed standard: ATG is a pivotal immunosuppressive therapy utilized in the management of T-cell-mediated rejection and steroid-resistant rejection among renal transplant recipients ; an IL-2 receptor antagonist (basiliximab) is not an appropriate substitute for treatment of established rejection, so step-therapy requirements should be waived - Dosing requested matches the FDA-approved regimen of 1.5 mg/kg of body weight administered daily for 4 to 7 days for induction, or a 7 to 14 day course of daily infusion of 1.5 mg/kg of Thymoglobulin for treatment of acute rejection, consistent with the package insert and LiverTox/NIH summaries - Thymoglobulin is preferred over equine ATG in high-risk recipients: multiple studies have indicated that thymoglobulin is favored in comparison to other induction agents for patients who have increased risk of developing post-transplant complications, such as elderly patients, patients undergoing a repeat transplantation, and patients in which minimization of use of steroids or CNIs post-operation is recommended — relevant for the Medicare Advantage population - Humana's own policy framework grants continuity-of-care protection: Humana does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to enrollment , and members can request expedited exception reviews for step therapy prior authorization requests - Contraindication-based denials should be rebutted with documentation that the patient has no history of allergy or anaphylaxis to rabbit proteins or to any product excipients, or active acute or chronic infections that contraindicate any additional immunosuppression , satisfying the only FDA-labeled contraindications

## Why Humana Denied rATG as "Non-Formulary" — and How to Appeal

Rabbit anti-thymocyte globulin (rATG) may be classified as non-formulary or placed on a restricted tier in Humana's drug formulary, meaning it requires additional authorization steps or is not covered without a formulary exception. This classification can result in denial at the pharmacy or during a prior-authorization review. Non-formulary denials are administrative in nature and are among the most routinely overturned denial types when the clinical rationale for the specific agent is documented.

Formulary decisions are made at the plan level based on cost and utilization considerations, not necessarily on the clinical needs of individual patients. Humana's formulary exception process exists precisely to address cases where the formulary alternative is medically inappropriate for a specific patient.

## Why This Denial Is Appealable

Humana is required to have a formulary exception process. If rATG is the clinically appropriate agent for your condition — and no formulary alternative is equally safe and effective for you specifically — you are entitled to a formulary exception. Transplant-specific agents like rATG often have no true therapeutic equivalent for the indication being treated, which is a strong exception basis. Additionally, switching a stable transplant patient away from an established immunosuppressive protocol carries its own clinical risks, which your prescriber can document.

## Federal Appeal Framework

• Formulary exception request: This is the first step — file a formulary exception with clinical documentation before or alongside the internal appeal.
• Internal appeal: File within the deadline on your Explanation of Benefits (EOB), typically 180 days from the denial date.
• ACA §2719 / external review: After a final internal denial, you are entitled to independent external review. The standard window is approximately four months from the final internal denial. Expedited review (72-hour decision) is available for urgent clinical situations.
• ERISA §503: Employer-sponsored plan members are entitled to full disclosure of the formulary exception criteria and a full-and-fair review of the exception request.

## Concrete Appeal Steps

1. Obtain the denial letter and Humana's published formulary, identifying the tier placement of rATG and the formulary exception criteria. 2. Identify any formulary alternatives Humana lists as preferred and have your clinician document why each is clinically inappropriate for your specific case. 3. Ask your transplant physician or specialist to submit a formulary exception request with a supporting medical-necessity letter. 4. File the internal appeal in parallel, incorporating the same clinical documentation. 5. If denied, escalate to external review.

## Documentation to Gather

• Prescriber medical-necessity letter: Your treating specialist should explain why rATG is the medically necessary agent for your specific condition and why any formulary-preferred alternative is clinically inappropriate, insufficient, or carries unacceptable risk for you.
• Formulary alternative assessment: A clinician note or letter specifically addressing each formulary-preferred alternative, documenting why it is not appropriate (e.g., prior failure, contraindication per the prescribing information, documented intolerance, or clinical incompatibility with your transplant protocol).
• Diagnosis and treatment history: Chart notes confirming your diagnosis and the clinical context requiring rATG, including any prior therapies and outcomes.
• Transplant or specialist protocol documentation: If rATG is part of an established institutional protocol or professional society guideline for your indication, reference the guideline organization by name.

## Criteria-Mapping Structure

Obtain Humana's formulary exception policy and the criteria for approving a non-formulary exception. Build a two-column table: left column lists each exception criterion; right column cites the chart note, clinician letter, or record that satisfies it. Pay particular attention to the criterion requiring that the formulary alternative be inadequate or contraindicated — document this with the greatest specificity your clinician can provide.